Hedgehog Signalling in Androgen Independent Prostate Cancer

European Urology

Volumn 54, Issue 6, 2008, Pages 1333-1343

  Shaw, Greg ^a   Price, Anna M ^a   Ktori, Elena ^a   Bisson, Isabelle ^a   Purkis, Patricia E ^a   McFaul, Siobhan ^a   Oliver, R Tim D ^a   Prowse, David M ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Androgen independent prostate cancer; Circulating tumour cells; Cyclopamine; Hedgehog signaling; LNCaP; PTCH

Indexed keywords

ACETYLSALICYLIC ACID; ANDROGEN; CISPLATIN; CYCLOPAMINE; DEXAMETHASONE; ETOPOSIDE; GEFITINIB; LOMUSTINE; SONIC HEDGEHOG PROTEIN;

ADULT; ADVANCED CANCER; AGED; ANDROGEN DEFICIENCY; ANDROGEN INDEPENDENT PROSTATE CANCER; ARTICLE; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER REGRESSION; CELL PROLIFERATION; CONTROLLED STUDY; DD3 GENE; GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; METASTASIS INHIBITION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

AGED; AGED, 80 AND OVER; ANDROGENS; HEDGEHOG PROTEINS; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 45849143363     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2008.01.070     Document Type: Article

References (26)

1. Shaw G.L., Wilson P., Cuzick J., et al. International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a meta-analysis of 1446 patients. BJU Int 99 (2007) 1056-1065
2. Shamash J., Dancey G., Barlow C., et al. Chlorambucil and lomustine (CL56) in absolute hormone refractory prostate cancer: re-induction of endocrine sensitivity an unexpected finding. Br J Cancer 92 (2005) 36-40
3. Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513-1520
4. Mimeault M., Moore E., Moniaux N., et al. Cytotoxic effects induced by a combination of cyclopamine and gefitinib, the selective Hedgehog and epidermal growth factor receptor signaling inhibitors, in prostate cancer cells. Int J Cancer 118 (2006) 1022-1031
5. Ingham P.W., and McMahon A.P. Hedgehog signaling in animal development: paradigms and principles. Genes Dev 15 (2001) 3059-3087
6. Karhadkar S.S., Bova G.S., Abdallah N., et al. Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature 431 (2004) 707-712
7. Shaw A., and Bushman W. Hedgehog signaling in the prostate. J Urol 177 (2007) 832-838
8. Lo Celso C., Prowse D.M., and Watt F.M. Transient activation of beta-catenin signalling in adult mouse epidermis is sufficient to induce new hair follicles but continuous activation is required to maintain hair follicle tumours. Development 131 (2004) 1787-1799
9. Datta S., and Datta M.W. Sonic Hedgehog signaling in advanced prostate cancer. Cell Mol Life Sci 63 (2006) 435-448
10. Sheng T., Li C., Zhang X., et al. Activation of the Hedgehog pathway in advanced prostate cancer. Mol Cancer 3 (2004) 29
11. Cristofanilli M., Hayes D.F., Budd G.T., et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 23 (2005) 1420-1430
12. Moreno J.G., Miller M.C., Gross S., et al. Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology 65 (2005) 713-718
13. van Bokhoven A., Varella-Garcia M., Korch C., et al. Molecular characterization of human prostate carcinoma cell lines. Prostate 57 (2003) 205-225
14. Thalmann G.N., Anezinis P.E., Chang S.M., et al. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 54 (1994) 2577-2581
15. Chen C.D., Welsbie D.S., Tran C., et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 10 (2004) 33-39
16. Chen J.K., Taipale J., Cooper M.K., and Beachy P.A. Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. Genes Dev 16 (2002) 2743-2748
17. Allard W.J., Matera J., Miller M.C., et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 10 (2004) 6897-6904
18. Moreno J.G., O'Hara S.M., Gross S., et al. Changes in circulating carcinoma cells in patients with metastatic prostate cancer correlate with disease status. Urology 58 (2001) 386-392
19. O'Hara S.M., Moreno J.G., Zweitzig D.R., et al. Multigene reverse transcription-PCR profiling of circulating tumor cells in hormone-refractory prostate cancer. Clin Chem 50 (2004) 826-835
20. Shaw G., Oliver R.T.D., Purkiss T., and Prowse D.M. Re: Christine McKillop. Interview with Jack Schalken: PCA3 and its use as a diagnostic test in prostate cancer [interview published in Eur Urol 2006;50:153-4]. Eur Urol 51 (2007) 860-862
21. de Kok J.B., Verhaegh G.W., Roelofs R.W., et al. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 62 (2002) 2695-2698
22. Sanchez P., Hernandez A.M., Stecca B., et al. Inhibition of prostate cancer proliferation by interference with SONIC HEDGEHOG-GLI1 signaling. Proc Natl Acad Sci USA 101 (2004) 12561-12566
23. Walsh P.C. Hedgehog signalling in prostate regeneration, neoplasia and metastasis. J Urol 173 (2005) 1169
24. Tabs S., and Avci O. Induction of the differentiation and apoptosis of tumor cells in vivo with efficiency and selectivity. Eur J Dermatol 14 (2004) 96-102
25. Mimeault M., Johansson S.L., Vankatraman G., et al. Combined targeting of epidermal growth factor receptor and Hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells. Mol Cancer Ther 6 (2007) 967-978
26. Kasper M., Schnidar H., Neill G.W., et al. Selective modulation of Hedgehog/GLI target gene expression by epidermal growth factor signaling in human keratinocytes. Mol Cell Biol 26 (2006) 6283-6298